DBV Technologies SA
DBVTHealthcare|Biotechnology|France
$16.49
+0.41 (+2.55%)
Tangible Book
$3.53
Earnings Power
$2.43
About
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
Stock Price
+52.2%(1Y)
Pipeline Summary
18 total trials4
Phase 1
6
Phase 2
7
Phase 3
0
Phase 4
Completed: 12NO_LONGER_AVAILABLE: 1Active: 1Unknown: 2Recruiting: 1AVAILABLE: 1
Active Trials (2)
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
NCT05741476Allergy, Peanut
Phase 3Active
Enrollment: 600 participants
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
NCT07003919Allergy
Phase 3Recruiting
Enrollment: 480 participants
BioScore
4.4/10
Cautious
Ownership
Recent Insider Trades
Mohideen PharisSELL
2026-01-29534 shares @ $4.86
EPIC BpifranceSELL
2025-12-183,369,093 shares @ $4.6
Mohideen PharisSELL
2025-11-218,120 shares @ $2.86
Mohideen PharisSELL
2025-07-29464 shares @ $2.22
Mohideen PharisSELL
2025-05-22397 shares @ $1.84
Recent News
2026-06-30 14:41:24
2026-06-30 13:50:27
2026-06-30 11:50:47
2026-06-30 10:32:06
2026-06-29 20:29:58
Data last updated: Jul 13, 2026, 12:48 PM